Drug news
FDA grants extended approval for Trisenox to treat acute promyelocytic leukemia
Teva Pharmaceutical Industries Ltd. announced that the FDA has approved the use of Trisenox (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.